AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

30/09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
05/26/05	€0.6430	+5.93%
04/26/04	€0.6070	+11.99%
03/26/03	€0.5420	+1.69%
31/26/31	€0.5330	-4.31%
30/26/30	€0.5570	-3.97%

Delayed Quote Deutsche Boerse AG

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Tradegate Other stock markets 01:05:37 05/08/2026 pm IST			5-day change	1st Jan Change
0.6950 ^EUR	+14.50%		+10.86%	-52.86%

13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules

Market Cap	5.18Cr 5.99Cr 4.83Cr 4.45Cr 8.39Cr 569.24Cr 8.49Cr 57Cr 22Cr 284.82Cr 22Cr 22Cr 943.3Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.18Cr 5.99Cr 4.83Cr 4.45Cr 8.39Cr 569.24Cr 8.49Cr 57Cr 22Cr 284.82Cr 22Cr 22Cr 943.3Cr	EV / Sales 2026 *	43.2x	EV / Sales 2027 *	39.9x
Free-Float	63.24%	Yield 2026 *	-	Yield 2027 *	-

13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
29/06	AB Science completes Step 3 of a Phase 1 study
18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib

04/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
01/07	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL

AB Science Share Price Deutsche Boerse AG

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/07	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
13/07	Wall Street ne chômera pas le 14 juillet
10/07	AB Science rationalise son portefeuille et se recentre sur deux molécules
10/07	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
08/07	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

1 day	+14.50%
1 week	+10.86%
Current month	+20.64%
1 month	-15.73%
3 months	-35.38%
6 months	-53.61%
Current year	-52.86%

1 week	0.53	0.64
1 month	0.52	0.76
Current year	0.52	1.55
1 year	0.52	1.55
3 years	0.52	3.88
5 years	0.52	14.53
10 years	0.52	20.1

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+14.50%	+10.86%	-	-	5.97Cr
MERCK & CO., INC.	+0.77%	-1.07%	+59.64%	+21.57%	32TCr
MERCK KGAA	-0.92%	-0.07%	+34.38%	-9.40%	7.33TCr
HALOZYME THERAPEUTICS, INC.	+0.15%	+0.43%	+37.54%	+99.10%	987.22Cr
KYOWA KIRIN CO., LTD.	+0.10%	-7.59%	-4.29%	-6.23%	814.85Cr
SK BIOPHARMACEUTICALS CO., LTD.	+2.76%	+3.14%	-14.67%	-14.85%	437.95Cr
YUHAN CORPORATION	+0.40%	+6.22%	-33.30%	+7.29%	391.03Cr
BETTA PHARMACEUTICALS CO., LTD.	+2.46%	+2.51%	-14.87%	+21.19%	362.48Cr
SUPERNUS PHARMACEUTICALS, INC.	+9.46%	+1.72%	+26.22%	+46.88%	251.4Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.19%	+6.42%	-2.77%	-3.33%	224.06Cr
Average	+2.98%	-0.50%	+9.76%	+18.02%	4.71TCr
Weighted average by Cap.	+0.55%	-1.99%	+50.74%	+16.99%

	2026 *	2027 *
Net sales	12L 13.86L 11.19L 10.29L 19.42L 13Cr 19.64L 1.31Cr 51.59L 6.59Cr 52.04L 50.89L 22Cr	13L 15.01L 12.12L 11.15L 21.04L 14Cr 21.28L 1.42Cr 55.89L 7.14Cr 56.37L 55.13L 24Cr
Net income	-	-
Net Debt	-	-